Cramer Remix: This blue stock is red hot

Scott Mlyn | CNBC. Jim Cramer advised which stocks should be left alone with the upcoming Brexit vote.·CNBC

Jim Cramer sees investors are fraught right now, because of the potential for a very difficult day of events on Friday. Worried investors hammered the market Thursday.

"Unfortunately, at least for the bulls, we have not one, not two, but three big bad events staring us right in the face," the "Mad Money" host said. (Tweet This)

The first of the big events on Friday morning is the Labor Department's employment report. Cramer has done extensive research on this, and warned that all non-farm payroll numbers are very important. All it takes is one number to determine the direction that the market is headed.

The next issue is Greece. Cramer said on Wednesday that he thinks the media has hyped the issue too much, but that doesn't mean it has gone away.

The third issue on Cramer's radar for Friday is the big OPEC meeting. In Cramer's opinion, it is pretty obvious that Saudi Arabia wants to maintain its market share and is willing to do so by any means necessary.

"I'd be remiss if I didn't acknowledge that these are real problems. There's typically a relief rally that comes after these big bad events. However, that might not occur until next Tuesday," Cramer said.

Read More Cramer: Brace yourself big bad jobs, oil & Greece

With the doom and gloom of three big headwinds for Friday out of the way, Cramer decided to talk about what he considers to be the hottest stock on the market right now.

Alder Biopharmaceuticals is a small-cap developmental stage biotech company, and it has doubled since April. Wowzer!

Some of the rebound is because the stock was recovering from a 24 percent pullback the previous month, but a lot of it was due to the market's newfound love for biotech and Alder.

Alder develops antibody based therapies for chronic migraines and inflammatory diseases like arthritis, and the stock was red hot when the company released extremely positive data surrounding its treatment for migraines.

Can it continue to skyrocket? To find out, Cramer spoke with Alder Biopharmaceuticals' co-founder and CEO, Dr. Randall Schatzman. The CEO explained that there are currently 36 million patients who suffer from migraines, and of those patients, about half get five or more migraines every month.

"The target that we are going after seems to be the primary initiating event for migraine. And by having a long acting safe agent onboard like a therapeutic antibody, what we are able to do is prevent that initiation from firing off the migraine at the get go," Schatzman said.

On Thursday, the rumor mill was swirling over possible merger talks between T-Mobile (NYSE: TMUS) and Dish Network (NASDAQ: DISH). As a result, both stocks shot through the roof, which left Cramer thinking-how do you kill a rumor that makes so much sense?

In Cramer's perspective, the merged company would be very attractive. Dish has the spectrum that is desperately needed by a big phone company, along with a television feed. T-Mobile is the most aggressive carrier out there, with the fastest growth, but it needs the spectrum.

"John Legere is a rebel with a cause, aspiring to have the best phone company on Earth. Charlie Ergen is a big thinker who has always tried to make Dish into a powerhouse. Both men are comfortable being in uber-deal mode," the "Mad Money" host said.

Ultimately, they might not be able to agree on a price and the deal could be derailed, but in this case, Cramer thinks the leak of rumors is legit.

"If Ergen and Legere can come to terms, you're going to have a new colossal uncarrier dog with a television tail," Cramer said.

Read More Cramer: T-Mobile + Dish = The perfect marriage

On a day when individual stocks were getting slammed at the mercy of Europe's financial negotiations with Greece, Jim Cramer thought this would be a good time to highlight an individual company that has managed to take its own destiny into its hands.

The "Mad Money" host considers the amazing story of Carnival (NYSE: CCL) to be one of the most impressive turnaround stories of our era

Yet despite these issues, Carnival is still going strong. It has taken the bull by the horns in repairing its image, for example by launching a social impact cruise line where volunteers can take vacation and serve communities in need at the same time.

How the heck did Carnival pull off such an impressive turnaround? To get the inside scoop, Cramer sat down with Carnival CEO Arnold Donald.

"Very simply, we started with a great company, so we had a fantastic foundation," Donald said.

The key, he says, was aligning the nine brands that they had at the time around the same common objectives. Then, the brands had to communicate, collaborate and coordinate with one another.

Read More Cramer: Carnival's most impressive turnaround ever

In the Lightning Round, Cramer gave his take on a few caller favorite stocks:

Baxter International: "I've been pushing in 'Get Rich Carefully' that Baxter should break up, and that's what it is doing. People are freaking out and they don't like the action in the stock. I say have patience."

Taser International: "I think Taser is the answer for a lot of the problems we read about...look,, law enforcement is a tough job, but I do think that Taser answers a lot of questions including the cloud-based security product so I say it is good."

Read More Lightning Round: This big data play stays hot



More From CNBC

Advertisement